[go: up one dir, main page]

WO2007116428A8 - Composition pharmaceutique orale contenant de la cystine ou de la cysteine associee a de la glutathione pour la prevention et le traitement du stress oxydant resultant de l'hemodialyse, et dispositif medical pour l'administration de ladite composition - Google Patents

Composition pharmaceutique orale contenant de la cystine ou de la cysteine associee a de la glutathione pour la prevention et le traitement du stress oxydant resultant de l'hemodialyse, et dispositif medical pour l'administration de ladite composition

Info

Publication number
WO2007116428A8
WO2007116428A8 PCT/IT2007/000261 IT2007000261W WO2007116428A8 WO 2007116428 A8 WO2007116428 A8 WO 2007116428A8 IT 2007000261 W IT2007000261 W IT 2007000261W WO 2007116428 A8 WO2007116428 A8 WO 2007116428A8
Authority
WO
WIPO (PCT)
Prior art keywords
cysteine
haemodialysis
pharmaceutical composition
composition containing
oxidative stress
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IT2007/000261
Other languages
English (en)
Other versions
WO2007116428A2 (fr
WO2007116428A3 (fr
Inventor
Francesco Santangelo
Francesco Paolo Pilato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio3 Research Srl
Original Assignee
Bio3 Research Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio3 Research Srl filed Critical Bio3 Research Srl
Priority to MX2008012974A priority Critical patent/MX2008012974A/es
Publication of WO2007116428A2 publication Critical patent/WO2007116428A2/fr
Publication of WO2007116428A8 publication Critical patent/WO2007116428A8/fr
Publication of WO2007116428A3 publication Critical patent/WO2007116428A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition pharmaceutique orale contenant de la cystine ou de la cystéine associée à de la glutathione, pour la prévention et le traitement du stress oxydant résultant de l'hémodialyse chez les patients présentant une insuffisance rénale chronique.
PCT/IT2007/000261 2006-04-10 2007-04-06 Composition pharmaceutique orale contenant de la cystine ou de la cysteine associee a de la glutathione pour la prevention et le traitement du stress oxydant resultant de l'hemodialyse, et dispositif medical pour l'administration de ladite composition Ceased WO2007116428A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2008012974A MX2008012974A (es) 2006-04-10 2007-04-06 Composicion farmaceutica oral que contiene cistina o cisteina con glutationa, para la prevencion y el tratamiento de tension oxidante originada por hemodialisis, y dispositivo medico para su administracion.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000206A ITRM20060206A1 (it) 2006-04-10 2006-04-10 Composizione farmaceutica orale contenente cistina o cisteina con glutatione per la prevenzione ed il trattamento dello stress ossidativo da emodialisi e dispositivo medico di somministrazione
ITRM2006A000206 2006-04-10

Publications (3)

Publication Number Publication Date
WO2007116428A2 WO2007116428A2 (fr) 2007-10-18
WO2007116428A8 true WO2007116428A8 (fr) 2007-12-13
WO2007116428A3 WO2007116428A3 (fr) 2008-03-13

Family

ID=38480485

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2007/000261 Ceased WO2007116428A2 (fr) 2006-04-10 2007-04-06 Composition pharmaceutique orale contenant de la cystine ou de la cysteine associee a de la glutathione pour la prevention et le traitement du stress oxydant resultant de l'hemodialyse, et dispositif medical pour l'administration de ladite composition

Country Status (4)

Country Link
KR (1) KR20090024673A (fr)
IT (1) ITRM20060206A1 (fr)
MX (1) MX2008012974A (fr)
WO (1) WO2007116428A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2527802B (en) * 2014-07-02 2019-10-16 Olimed Ltd An orally disintegrating tablet with differentiated absorption
FR3092491B1 (fr) * 2019-02-11 2021-11-12 Bretagne Chimie Fine Utilisation non-thérapeutique par voie orale d’une composition pour blanchir et/ou éclaircir la peau comprenant de la cystine et du glutathion dans un rapport cystine/glutathion allant de 1,5 à 4
US20230372272A1 (en) * 2020-09-28 2023-11-23 Georgia Tech Research Corporation Use of cystine and derivatives thereof as anti-thrombotic and thrombolytic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0146265B1 (fr) * 1983-11-15 1991-04-03 Kyowa Hakko Kogyo Co., Ltd. Procédé de production d'un composé à partir de son précurseur en utilisant l'activité enzymatique d'une bactérie
US5576287A (en) * 1994-04-29 1996-11-19 Wake Forest University Method for treating acute renal disease and failure
US6228347B1 (en) * 1997-12-01 2001-05-08 Thione International, Inc. Antioxidant gel for gingival conditions
KR100390630B1 (ko) * 1999-07-02 2003-07-07 이희발 항 산화제를 함유한 복막투석액
ITMI20032528A1 (it) * 2003-12-19 2005-06-20 Francesco Santangelo Uso di cistina o di cisteina per la prevenzione e il

Also Published As

Publication number Publication date
WO2007116428A2 (fr) 2007-10-18
MX2008012974A (es) 2008-12-18
WO2007116428A3 (fr) 2008-03-13
KR20090024673A (ko) 2009-03-09
ITRM20060206A1 (it) 2007-10-11

Similar Documents

Publication Publication Date Title
EA201100958A1 (ru) Фармацевтическая пероральная дозированная лекарственная форма на основе ингибиторов dpp iv
EA200701146A1 (ru) Композиция, содержащая орнитин и фенилацетат или фенилбутират, для лечения печеночной энцефалопатии
EP2982696A3 (fr) Traitement de la leucémie lymphoblastique aiguë
IL219915A0 (en) Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
ES2356883A1 (es) Composicion para el tratamiento del dolor y/o la inflamacion.
NZ594814A (en) Peptide that is derived from a milk protein and has an antioxidative effect and also acts as a blood adiponectin level increase promotion and/or decrease inhibition agent
WO2008022974A3 (fr) Composition antidiabetique contenant de l'acide chicorique et/ou l'un de ses metabolites
MX2010001849A (es) Depsipeptidos ciclicos.
WO2008046865A3 (fr) Système d'alimentation à long terme pour personnes agées
WO2005077103A3 (fr) Compositions et methodes de modification et de prevention de l'infectiosite du coronavirus du sras
WO2008017752A3 (fr) Extrait d ' eucalyptus, son procede de preparation et ses utilisations therapeutiques
WO2009068708A3 (fr) Composition pharmaceutique à libération prolongée de somatostatine ou d'un analogue de celle-ci
WO2009144551A3 (fr) Utilisation de la dronédarone ou un sel pharmaceutiquement acceptable de celle-ci, pour la préparation d’un médicament permettant la régulation du niveau de potassium dans le sang
WO2008008882A3 (fr) Modulateur du récepteur des glucocorticoïdes et procédés d'utilisation
WO2007116428A3 (fr) Composition pharmaceutique orale contenant de la cystine ou de la cysteine associee a de la glutathione pour la prevention et le traitement du stress oxydant resultant de l'hemodialyse, et dispositif medical pour l'administration de ladite composition
TW200700071A (en) Novel use
EP2193789B8 (fr) Utilisation du 5-methyl-1,3-benzenediol ou de ses derives dans la preparation de medicaments ou de nourriture fonctionnelle destines au traitement ou a la prevention de la depression
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
WO2007116297A3 (fr) Utilisation d'aminaphtone pour la préparation d'un médicament destiné au traitement d'artériopathies
EP1997503A3 (fr) Traitement de la mélanome avec peptides de thymosine alpha
EA200970877A1 (ru) Композиция, пригодная для предупреждения диабета 2 типа и его осложнений у пациентов с предиабетом с резистентностью к инсулину
EP1843781A4 (fr) Composition pour la prevention, le traitement et le diagnostic de maladies chroniques inflammatoires des voies aeriennes
ZA200705349B (en) Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
EA200970798A1 (ru) Композиция для лечения диабета 2 типа

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07736765

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/012974

Country of ref document: MX

Ref document number: 4082/KOLNP/2008

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020087027326

Country of ref document: KR

122 Ep: pct application non-entry in european phase

Ref document number: 07736765

Country of ref document: EP

Kind code of ref document: A2